Search
Now showing items 1-10 of 40
Mechanisms of tubulin binding ligands to target cancer cells: Updates on their therapeutic potential and clinical trials
(Bentham Science Publishers B.V., 2017)
Background: A number of chemically diverse substances bind to the tubulin and inhibit cell proliferation by disrupting microtubule dynamics. There are four binding sites for the ligands binding to the tubulin; taxane/epothilone ...
Recent synthetic strategies for monocyclic azole nucleus and its role in drug discovery and development
(Bentham Science Publishers B.V., 2018)
Background: In recent years, the development and diversification of heterocyclic compounds has become central to the discovery of bioactive compounds with novel or improved pharmacological properties. In particular, ...
Synthesis, biological evaluation and molecular modeling studies of phenyl-/benzhydrylpiperazine derivatives as potential MAO inhibitors
(Academic Press Inc., 2018)
Monoamine oxidase inhibitors (MAOIs) are potential drug candidates for the treatment of various neurological disorders like Parkinson's disease, Alzheimer's disease and depression. In the present study, two series of ...
Synthesis, Biological Evaluation and Molecular Modeling Studies of Propargyl‐Containing 2,4,6‐Trisubstituted Pyrimidine Derivatives as Potential Anti‐Parkinson Agents
(Wiley, 2018)
Monoamine oxidase B (MAO‐B) inhibitors are potential drug candidates for the treatment of various neurological disorders including Parkinson's disease. A total of 20 new propargyl‐containing 2,4,6‐trisubstituted pyrimidine ...
Recent developments on 1,2,4-triazole nucleus in anticancer compounds: A review
(Bentham Science Publishers B.V., 2016)
1,2,4 triazole is an important nucleus present in a large number of compounds. More than thirty-five compounds containing this nucleus are introduced into the market. 1,2,4-triazole nucleus is stable to metabolism and acts ...
A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
(2017)
The monoamine oxidase (MAO) enzyme is responsible for the deamination of monoamine neurotransmitters and regulates their concentration in the central and peripheral nervous systems. Imbalance in the concentration of ...
Pyrrolo- and pyridomorphinans: Non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists
(Elsevier, 2014)
Opioid ligands have found use in a number of therapeutic areas, including for the treatment of pain and opiate addiction (using agonists) and alcohol addiction (using antagonists such as naltrexone and nalmefene). The ...
Regioselective alkylation of 1,2,4-triazole using ionic liquids under microwave conditions
(Walter de Gruyter GmbH, 2016)
1-Substituted 1,2,4-triazole derivatives present in a large number of compounds and display a variety of bioactivities such as antibiotic, anti-inflammatory, anti-diabetic, antipsychotic, and anticancer. A regioselective ...
Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders
(Royal Society of Chemistry, 2016)
Monoamine oxidase (MAO) enzyme catalyzes the oxidative deamination of xenobiotic and endogenous amines including many neurotransmitters. The MAO enzyme exists in two isoforms; MAO-A and MAO-B and these isoforms display ...
Role of genomic alterations in HER2 positive breast carcinoma: Focus on susceptibility and trastuzumab-therapy
(Bentham Science Publishers B.V., 2017)
Background: Breast cancer is the most frequently diagnosed life-threatening malignancy among women, across the globe. HER2 positive is a distinct breast cancer subtype, on account of its unique biology and physiological ...